Business Description
Enorama Pharma AB
ISIN : SE0008216329
Total Employee Number:
4Compare
Compare
Traded in other countries / regions
ERMA.Sweden IPO Date
2016-06-10Description
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | -1.6 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -8.28 | |||||
Beneish M-Score | -5.94 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -57.3 | |||||
3-Year EBITDA Growth Rate | 27.5 | |||||
3-Year EPS without NRI Growth Rate | 29.9 | |||||
3-Year FCF Growth Rate | 29.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 23.6 | |||||
9-Day RSI | 33.09 | |||||
14-Day RSI | 38.03 | |||||
3-1 Month Momentum % | -8.4 | |||||
6-1 Month Momentum % | -79.5 | |||||
12-1 Month Momentum % | -84.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.64 | |||||
Quick Ratio | 0.59 | |||||
Cash Ratio | 0.5 | |||||
Days Inventory | 131.9 | |||||
Days Sales Outstanding | 157.41 | |||||
Days Payable | 160.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -86.1 | |||||
Shareholder Yield % | -100.97 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -335.08 | |||||
Operating Margin % | -2613.85 | |||||
Net Margin % | -2992.8 | |||||
EBITDA Margin % | -2510.91 | |||||
FCF Margin % | -2113.11 | |||||
OCF Margin % | -2113.11 | |||||
ROA % | -313.17 | |||||
ROIC % | -670.18 | |||||
3-Year ROIIC % | 49.86 | |||||
ROC (Joel Greenblatt) % | -197067.86 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 8.5 | |||||
EV-to-EBIT | -0.23 | |||||
EV-to-EBITDA | -0.23 | |||||
EV-to-Revenue | 5.71 | |||||
EV-to-FCF | -0.34 | |||||
Price-to-GF-Value | 0.62 | |||||
Earnings Yield (Greenblatt) % | -444.81 | |||||
FCF Yield % | -242.32 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Enorama Pharma AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 2.181 | ||
| EPS (TTM) (kr) | -0.91 | ||
| Beta | -1.4697 | ||
| 3-Year Sharpe Ratio | -0.07 | ||
| 3-Year Sortino Ratio | -0.14 | ||
| Volatility % | 86.2 | ||
| 14-Day RSI | 38.03 | ||
| 14-Day ATR (kr) | 0.028862 | ||
| 20-Day SMA (kr) | 0.29795 | ||
| 12-1 Month Momentum % | -84.61 | ||
| 52-Week Range (kr) | 0.211 - 3.58 | ||
| Shares Outstanding (Mil) | 74.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Enorama Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Enorama Pharma AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-18 | In 130 days | ||
| Second quarter earnings results for 2026 | 2026-08-19 | In 39 days | ||
| General meeting for 2025 | 2026-06-16 14:30 | 0.34 (-5.57%) | ||
| First quarter earnings results for 2026 | 2026-05-20 | 0.30 (+5.63%) | ||
| Annual report for 2025 | 2026-04-24 | 0.29 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-18 | 0.80 (-7.23%) | ||
| Third quarter earnings results for 2025 | 2025-11-19 | 2.61 (-6.79%) | ||
| Second quarter earnings results for 2025 | 2025-08-20 | 2.61 (-10.00%) | ||
| First quarter earnings results for 2025 | 2025-05-21 | 2.78 (+5.30%) | ||
| General meeting for 2024 | 2025-04-08 14:30 | 1.95 (+0.26%) |
Show
Entries
Enorama Pharma AB Frequently Asked Questions
What is Enorama Pharma AB(OSTO:ERMA)'s stock price today?
The current price of OSTO:ERMA is kr0.26. The 52 week high of OSTO:ERMA is kr3.58 and 52 week low is kr0.21.
When is next earnings date of Enorama Pharma AB(OSTO:ERMA)?
The next earnings date of Enorama Pharma AB(OSTO:ERMA) is 2026-08-19.
Does Enorama Pharma AB(OSTO:ERMA) pay dividends? If so, how much?
Enorama Pharma AB(OSTO:ERMA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Enorama Pharma AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers